Generic entry is usually treated like a countdown clock: once patents expire, prices fall, margins compress, and the market moves on. But that narrative misses a crucial reality in pharma: the most durable moat is often not the headline compound patent…

Biotech investing can feel like a high-wire act: one promising pipeline update and you’re soaring—one overlooked risk and you’re suddenly on the ground.
But the most common “fall” I see isn’t scientific. It’s legal.
In biotech, patents aren’t just pape…

Biosimilar entry windows aren’t won by spreadsheets—they’re won by judgment.
In the biosimilar market, timing is everything. A few months can mean millions in incremental revenue, market share, and negotiating leverage. Yet too many companies still t…

Generic and biosimilar development is a high-stakes game of timing, risk, and proof. Yet many teams still make go/no-go decisions with incomplete visibility into the patent landscape—until the litigation calendar forces the conversation.
Here’s the unc…

Designing Around the Moat: How Generic Developers Can Navigate Secondary Formulation Patents
In generic drug development, the real fight often isn’t the active ingredient—it’s the moat built around it.
For years, the industry has focused on the “primar…

Pharma doesn’t just “own” a drug patent. It manages time.
That’s the quiet strategy behind patent term extensions and secondary patents—tools that can stretch exclusivity, delay generic entry, and effectively turn a finite patent clock into a longer co…

Your pharmaceutical portfolio has a time bomb in it. Patent expiration data tells you where.
If you’re leading strategy, BD, or portfolio management in pharma, you already know the uncomfortable truth: the biggest threat to revenue often isn’t a failed…

The Hidden Dangers of Combining Lipitor with Salt Substitutes As we age, our bodies undergo a multitude of changes that… https://www.Drugchatter.com/chat/38920/are-there-any-dangers-in-using-lipitor-alongside-salt-substitutes/

Big Pharma loves a wall.
Not the kind you can climb— the kind you’re told is “impenetrable,” built from patents, continuations, and carefully timed filings. For years, the story has been simple: if you don’t have the biggest legal team, you don’t have …

Brands Don’t Launch “Competition” by Accident—They Do It to Win the Next Phase
There’s a quiet strategy playing out across pharma that most investors only notice after the fact: the authorized generic.
On the surface, it looks like a contradiction. Why…